Effects of magnesium supplementation on improving hyperglycemia, hypercholesterolemia, and hypertension in type 2 diabetes: A pooled analysis of 24 randomized controlled trials
Xu L, Li X, Wang X, Xu M
Frontiers in nutrition · 16 citas
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Natural Science Foundation of China
- Subvenciones
- National Natural Science Foundation of China (32102553)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2023-01-18 · Front Nutr · vol. 9 · pág. 1020327
- Editorial
- Frontiers Media
- Citado
- 25 citas · más que el 92% de estudios similares · 3.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 76 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Neurological Disorders and Treatments
- Palabras clave
- Medicine, Type 2 diabetes, Diabetes mellitus, Randomized controlled trial, Internal medicine, Magnesium, Endocrinology, Chemistry
4 autores
- Lianbin Xu🇨🇳Qingdao Agricultural University
- Xiuli Li🇨🇳Qingdao Agricultural University
- Xinhui Wang🇨🇳Zhejiang University
- Mingqing Xu🇺🇸🇨🇳 · autor de correspondenciaHarvard University; Shanghai Jiao Tong University; Center for Systems Biology
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Previous studies have demonstrated that diabetes is often accompanied with lower magnesium status. However, practical details regarding the influences of magnesium intervention on hyperglycemia, hypercholesterolemia, and hypertension in type 2 diabetes (T2D) need to be further investigated.
Methods
Web of Science, ScienceDirect, and PubMed were searched for relevant literatures published through April 30, 2022, and high-quality data were pooled to evaluate the effects of magnesium supplementation on glycemic, circulating lipids, and blood pressure control in T2D, and to explore the associated practical details.
Results
Pooled analyses of 24 randomized controlled trials with 1,325 T2D individuals revealed that subjects who received magnesium supplementation had statistically significant reductions in fasting plasma glucose, glycated hemoglobin, systolic blood pressure and diastolic blood pressure, with WMD values of -0.20 mM (95% CI: -0.30, -0.09), -0.22% (95% CI: -0.41, -0.03), -7.69 mmHg (95% CI: -11.71, -3.66) and -2.71 mmHg (95% CI: -4.02, -1.40), respectively. Detailed subgroup analyses demonstrated that health status of participants including age, body mass index, country, duration of disease, baseline magnesium level and baseline glycemic control condition as well as magnesium formulation, dosage and duration of intervention influenced the effects of magnesium addition. Dose-effect analysis showed that 279 mg/d for 116 d, 429 mg/d for 88 d and 300 mg/d for 120 d are the average optimal dosages and durations for improving glycemic, circulating lipids, and blood pressure controls, respectively.
Conclusion
Our findings provide clinically relevant information on the adjuvant therapy of magnesium for improving hyperglycemia, hypercholesterolemia, and hypertension in T2D.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.